



DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE  
\_\_\_\_\_  
PUBLIC HEALTH SERVICE

9 June 1959

National Institute of Mental Health  
Addiction Research Center  
U.S. Public Health Service Hospital  
Lexington, Kentucky

(b) (3)

H II

(b) (3)

Under separate cover we are forwarding you 2 gm of 1-(beta-diethylaminoethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole methanesulfonate (Ba-20684, NIH-7607, ARC I-G-2). This is an extremely potent material and care should be used in handling it; source was, of course, the Ciba company.

Also enclosing copy of a preliminary report on the addictiveness of two benzimidazole derivatives which was prepared for Dr. Nathan B. Eddy, Secretary of the Drug Addiction Committee. You will note this report indicates that Ba-20684 is 60 to 100 times as potent as morphine orally in man. Good morphine-like effects were obtained with a total dose of 0.25 mg. Dr. Fraser is to explore the dose range, particularly the higher dose range, using the oral route. He will also study parenteral administration.

Detailed pharmacological information is not yet available, however Ciba has indicated to me that they are preparing a brochure for clinical investigators which will contain all the information. When this is received it will be copied and sent to you.

Kindest personal regards,

Yours very sincerely,

*Harris Isbell*  
Harris Isbell, M. D.  
Director

HI:bws Also including a preliminary report on cross-tolerance between LSD and psilocybin

B-279